Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 2,500 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 2,500 shares of Entrada Therapeutics stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total transaction of $32,375.00. Following the completion of the sale, the chief financial officer directly owned 119,010 shares in the company, valued at approximately $1,541,179.50. The trade was a 2.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kory James Wentworth also recently made the following trade(s):

• On Tuesday, March 10th, Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.02, for a total transaction of $148,271.76.
• On Monday, March 9th, Kory James Wentworth sold 5,089 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.00, for a total value of $66,157.00.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.25, for a total value of $97,853.00.

Entrada Therapeutics Price Performance

Shares of NASDAQ TRDA traded down $0.33 on Thursday, hitting $13.15. The company’s stock had a trading volume of 178,008 shares, compared to its average volume of 225,838. The stock has a 50 day moving average of $11.74 and a 200-day moving average of $9.58. The company has a market capitalization of $503.38 million, a price-to-earnings ratio of -3.80 and a beta of -0.15. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $13.66.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.38. The company had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. Sell-side analysts expect that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TRDA. Cantor Fitzgerald started coverage on shares of Entrada Therapeutics in a report on Wednesday. They issued an “overweight” rating for the company. Wall Street Zen lowered Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. Finally, Oppenheimer initiated coverage on Entrada Therapeutics in a research note on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of TRDA. State of Wyoming lifted its stake in shares of Entrada Therapeutics by 130.9% in the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after acquiring an additional 4,295 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after acquiring an additional 3,707 shares during the last quarter. AXQ Capital LP acquired a new stake in Entrada Therapeutics during the 3rd quarter worth about $67,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Entrada Therapeutics during the second quarter valued at approximately $68,000. Finally, Inscription Capital LLC purchased a new stake in shares of Entrada Therapeutics in the third quarter valued at $69,000. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.